List of Excipients in Branded Drug BASIC CARE MICONAZOLE 3

« Back to Dashboard

Generic Drugs Containing BASIC CARE MICONAZOLE 3

Company	Ingredient	NDC	Excipient
L Perrigo Company	miconazole nitrate	0113-7070	BENZOIC ACID
L Perrigo Company	miconazole nitrate	0113-7070	CETYL ALCOHOL
L Perrigo Company	miconazole nitrate	0113-7070	ISOPROPYL MYRISTATE
L Perrigo Company	miconazole nitrate	0113-7070	POLYSORBATE 60
L Perrigo Company	miconazole nitrate	0113-7070	POTASSIUM HYDROXIDE
L Perrigo Company	miconazole nitrate	0113-7070	PROPYLENE GLYCOL
L Perrigo Company	miconazole nitrate	0113-7070	STEARYL ALCOHOL

What are the Most Frequently-Used Excipients in BASIC CARE MICONAZOLE 3?

# Of NDCs	Excipient
2	BENZOIC ACID
2	CETYL ALCOHOL
2	ISOPROPYL MYRISTATE
2	POLYSORBATE 60
2	POTASSIUM HYDROXIDE
2	PROPYLENE GLYCOL
2	STEARYL ALCOHOL

Last updated: September 25, 2026

Executive summary: Basic Care Miconazole 3 is an OTC vaginal antifungal product containing three 200 mg miconazole nitrate suppositories. Its commercial position depends more on low-cost manufacturing, retailer access, packaging, and consumer trust than on patent exclusivity. The formulation’s central excipient choice is a hydrogenated vegetable-oil suppository base, which supports dose delivery but creates leakage, softening, compatibility, and barrier-contraceptive warnings. The product has no meaningful active-ingredient patent barrier, no conventional prescription-drug Orange Book strategy, and limited regulatory exclusivity. Commercial opportunity exists in private-label scale, formulation upgrades, sustainable packaging, combination packs, and adjacent vaginal-health products.

Basic Care Miconazole 3 Excipient Strategy, Patent Position, and Commercial Opportunities

What is Basic Care Miconazole 3?

Basic Care Miconazole 3 is a three-day OTC vaginal antifungal product marketed under the Basic Care private-label brand. The standard product contains three vaginal suppositories, each delivering 200 mg of miconazole nitrate. Miconazole is an imidazole antifungal used for the treatment of uncomplicated vaginal yeast infections caused primarily by Candida species.

The “3” in Miconazole 3 refers to the three-dose treatment duration, not a 3% drug concentration. The product is generally positioned against branded and store-brand versions of Monistat 3.

Attribute	Basic Care Miconazole 3
Active ingredient	Miconazole nitrate
Dose	200 mg per vaginal suppository
Treatment duration	Three consecutive days
Route	Intravaginal
Regulatory category	OTC vaginal antifungal
Primary comparator	Monistat 3 and generic miconazole 3-day products
Likely dosage form	Vaginal suppository
Primary excipient function	Hydrogenated vegetable-oil base for drug dispersion and vaginal delivery
Patent exposure	No material composition-of-matter barrier expected
Orange Book status	Typically not applicable to an OTC monograph product

FDA regulations identify miconazole nitrate vaginal products among permitted OTC vaginal antifungal products when used in the specified dosage forms and concentrations. The applicable regulatory framework is the OTC monograph system rather than a new prescription-drug approval pathway. (U.S. Food and Drug Administration [FDA], 2023; Electronic Code of Federal Regulations [eCFR], 2024)

What excipients are used in Basic Care Miconazole 3?

The suppository version is generally formulated with hydrogenated vegetable oil as the principal inactive ingredient. The base is solid at room temperature and melts or softens after vaginal administration, allowing miconazole nitrate to disperse across the vaginal mucosa.

The commercial label for the suppository presentation identifies the formulation as a miconazole nitrate suppository with a hydrogenated vegetable-oil base. Cream presentations use a different excipient system and should not be treated as interchangeable for formulation, stability, or packaging analysis.

Excipient or excipient class	Primary role	Commercial significance
Hydrogenated vegetable oil	Suppository matrix, carrier, melting base	Controls firmness, melting, leakage, and release
Miconazole nitrate	Antifungal active ingredient	Requires uniform dispersion within the lipid base
Packaging film or blister materials	Physical protection and dose containment	Affects heat stability, migration, and shelf life
Applicator materials, where supplied	Intravaginal administration	Adds cost and user-experience considerations

A lipid suppository base has practical advantages. It is relatively simple to manufacture, avoids a water-containing system, and can support a low-cost unit-dose product. It also reduces the need for antimicrobial preservation used in aqueous creams.

The main limitation is physical behavior. Hydrogenated vegetable oils can soften during transport or storage, especially under elevated temperatures. The formulation may produce leakage after administration, and the product can leave an oily residue. These characteristics influence consumer satisfaction, package design, shipping controls, and complaint rates.

Why is the excipient strategy commercially important?

For a mature OTC product, excipients often determine the commercial performance more than the active ingredient. Miconazole nitrate is widely available from established suppliers. The differentiating variables are dose consistency, suppository integrity, ease of insertion, leakage control, shelf stability, packaging, and perceived cleanliness of use.

Dose uniformity and drug dispersion

Miconazole nitrate must remain uniformly distributed throughout the molten or semi-molten suppository mass. Manufacturing controls should address:

• Particle-size distribution of miconazole nitrate
• Wetting and dispersion in the lipid phase
• Mixing temperature and time
• Sedimentation during filling
• Fill-weight variation
• Content uniformity across the three-dose package

A poorly controlled lipid suspension can produce dose stratification, particularly if the active ingredient settles before the mass is filled. This creates both quality risk and potential regulatory exposure.

Melting behavior and leakage

The base should soften or melt sufficiently after administration while remaining stable under normal storage conditions. A narrow operating window can create problems:

• Too low a softening temperature may cause deformation in warm climates.
• Too high a melting point may delay drug release or create discomfort.
• Excessive liquefaction can increase leakage and consumer complaints.
• Inconsistent solidification can produce visual defects and fill-weight variation.

The formulation target should be linked to the intended distribution profile. A product sold through hot-weather retail channels may require greater thermal robustness than one distributed through controlled indoor environments.

Water activity and microbiological control

A substantially anhydrous suppository has lower microbiological risk than a water-based vaginal cream. That can simplify preservative strategy and reduce the burden associated with microbial growth during shelf life. It does not eliminate the need for microbial quality controls. Raw materials, manufacturing equipment, packaging operations, and finished-product testing remain relevant.

Packaging compatibility

The package must prevent physical damage and protect the lipid matrix from heat, oxygen, light, and contamination. Candidate systems include:

• PVC or multilayer blister packs
• Foil-laminate unit-dose packs
• Strip packs
• Individual wrapped suppositories placed in a carton

Foil-based structures may offer stronger protection against oxygen and moisture than basic plastic systems, but they can increase packaging cost. The optimal design depends on the intended shelf life, climate zones, retail handling, and sustainability requirements.

What formulations are protected by the Miconazole 3 excipient strategy?

The principal formulation opportunity is not a new active ingredient. It is an improved delivery system that maintains OTC monograph compliance while addressing the known weaknesses of lipid suppositories.

Hydrogenated vegetable-oil suppository

This is the lowest-complexity strategy. It supports private-label economics and can be manufactured using conventional melt-and-fill equipment. The commercial risks are leakage, heat sensitivity, oily residue, and limited perceived differentiation.

Hard-fat or semisynthetic glyceride base

A hard-fat base can provide more predictable melting behavior and improved structural integrity. It may also support tighter control over polymorphism than some vegetable-oil systems. The tradeoff is greater raw-material specification work and possible changes in release behavior.

Water-dispersible suppository base

A polyethylene glycol or other water-dispersible system could reduce oily residue and improve consumer perception. It may introduce new risks involving mucosal tolerability, hygroscopicity, brittleness, and slower dissolution. Such a system would require comparative release, stability, and irritation evaluation.

Bioadhesive or mucoadhesive platform

A mucoadhesive base could increase residence time and reduce leakage. It may support premium positioning, but the regulatory and development burden is higher. The product would need careful assessment of local tolerability, drug release, applicator performance, and whether the claims remain within the OTC monograph framework.

Cream or ovule alternative

A cream format can improve insertion and spreadability but generally requires a more complex excipient system. Oil-in-water creams require preservation and emulsion stability controls. Oil-based creams can also create condom and diaphragm compatibility concerns.

What is the FDA regulatory status of Basic Care Miconazole 3?

Basic Care Miconazole 3 is positioned as an OTC vaginal antifungal product under the FDA’s nonprescription drug framework. Miconazole nitrate vaginal products may be marketed when they meet applicable monograph conditions, including active ingredient, concentration, dosage form, labeling, and directions.

The product does not depend on a conventional new drug application exclusivity period. A company can market a compliant equivalent product without relying on an innovator approval, subject to applicable FDA requirements.

The principal regulatory controls are:

1. Compliance with the OTC vaginal antifungal monograph.
2. Drug listing and establishment registration.
3. Current good manufacturing practice compliance.
4. Product quality and stability testing.
5. Required consumer labeling and warnings.
6. Adverse-event reporting and post-market quality monitoring.

A reformulated product that introduces a new delivery claim, materially different dosage form, or non-monograph active-ingredient presentation could require a different regulatory analysis.

What is the Orange Book status of Basic Care Miconazole 3?

Basic Care Miconazole 3 is not expected to have a meaningful Orange Book listing strategy because it is an OTC monograph product rather than a prescription drug approved through a conventional NDA or ANDA pathway.

The absence of Orange Book-listed patents has several consequences:

• There is no standard Orange Book patent certification pathway for competitors.
• Paragraph IV litigation is generally not the central challenge mechanism.
• Generic competition can arise through compliant OTC marketing rather than an ANDA launch.
• Commercial barriers are based on manufacturing, distribution, branding, and retailer authorization.

The FDA Orange Book primarily identifies approved prescription drug products and related patent and exclusivity information. It is not a comprehensive register of all OTC monograph products. (FDA, 2024)

When does Miconazole 3 lose exclusivity?

Miconazole 3 has no meaningful remaining active-ingredient exclusivity. Miconazole was first developed and commercialized decades ago, and the molecule is now widely used in generic and OTC products.

Exclusivity category	Status
Composition-of-matter patent	Expired or commercially irrelevant
New chemical entity exclusivity	Expired
Prescription pediatric exclusivity	Not relevant to this OTC product
Orphan exclusivity	Not applicable
OTC monograph exclusivity	No conventional market exclusivity
Formulation exclusivity	Depends on specific claims and patents, but no known barrier to ordinary miconazole suppositories
Orange Book exclusivity	Not expected to apply

A company could obtain patents on a genuinely novel excipient system, delivery device, manufacturing process, or therapeutic use. Those rights would not restore exclusivity to ordinary miconazole nitrate suppositories.

What patent protection covers miconazole suppositories?

The commercial product is exposed to extensive freedom-to-operate space because basic miconazole nitrate vaginal formulations are mature. Any relevant historical patents covering the active molecule, ordinary vaginal use, or conventional dosage forms are likely expired.

Potentially relevant modern patent categories include:

Patent category	Relevance to Basic Care Miconazole 3	Risk level
Miconazole compound patents	Historical protection only	Low
Conventional 200 mg suppository	Likely expired or nonexclusive technology	Low
Hydrogenated vegetable-oil base	Usually broad, conventional formulation technology	Low
Specific polymorph or particle-size claims	Could affect supplier or process selection	Low to moderate
Mucoadhesive formulation	Relevant only to an improved delivery platform	Moderate
Novel applicator or packaging	Could create design-around issues	Low to moderate
Combination antifungal products	Separate patent and regulatory analysis	Moderate
Manufacturing process claims	Depends on supplier and process details	Moderate

Patent diligence should focus on active third-party rights around the selected excipient supplier, high-shear dispersion process, novel release profile, applicator design, and any premium product claims. The ordinary hydrogenated vegetable-oil suppository is unlikely to support a strong standalone patent position.

Are there Paragraph IV challenges or patent litigation risks?

No material Paragraph IV challenge is expected for a standard Basic Care Miconazole 3 OTC product. Paragraph IV certifications apply primarily to abbreviated applications for approved prescription drugs with Orange Book-listed patents. An OTC monograph product generally reaches the market through a different route.

Litigation risk is more likely to arise from:

• Trade dress or trademark disputes
• Private-label manufacturing agreements
• Product liability claims
• Quality failures
• Labeling or advertising disputes
• Patent claims directed to an improved delivery system
• Contract disputes involving retailer-exclusive supply

No major patent litigation barrier is inherent in the ordinary miconazole 3-day suppository format based on the product’s mature OTC status.

Which companies compete with Basic Care Miconazole 3?

The principal competitive set includes branded, generic, and private-label products:

Competitor category	Examples	Competitive basis
Branded OTC	Monistat 3	Consumer recognition and pharmacy presence
Store brands	Retailer-labeled miconazole 3 products	Price and shelf placement
Generic manufacturers	Multiple OTC suppliers	Supply reliability and cost
Alternative dosage forms	Miconazole 1, 7-day cream, external creams	Convenience, duration, and symptom profile
Alternative actives	Clotrimazole and tioconazole products	Brand and dosage-form differentiation

The strongest competitive pressure comes from retailer private labels. The active ingredient is standardized, switching costs are low, and consumers often select based on price, package format, perceived efficacy, and availability.

What commercial opportunities exist for Basic Care Miconazole 3?

Private-label manufacturing scale

The most direct opportunity is cost-efficient supply for large retailers and e-commerce channels. A manufacturer with validated melt-and-fill capacity, reliable miconazole sourcing, and strong packaging throughput can compete on landed cost.

Premium leakage-control formulation

A suppository that resists softening and reduces post-dose leakage could support a premium SKU. The commercial claim would need to remain consistent with substantiated product performance and FDA labeling requirements.

Sustainable excipient and packaging strategy

A plant-derived hydrogenated fat base and reduced-plastic packaging could appeal to consumers and retailers with sustainability programs. Claims would require substantiation, particularly for terms such as “natural,” “plant-based,” or “biodegradable.”

Multi-product vaginal-health portfolio

Miconazole 3 could anchor a broader portfolio containing:

• One-day miconazole products
• Seven-day lower-dose products
• External antifungal creams
• Vaginal moisturizers
• pH-support products
• Applicator-free formats
• Travel-size treatment kits

A portfolio approach increases retailer negotiating leverage and allows segmentation by treatment duration and price.

Combination packaging

A three-dose treatment kit with external symptom-relief cream, cleansing guidance, or an improved applicator could increase transaction value. Any additional active ingredient would require separate regulatory analysis.

Geographic expansion

The product can be adapted for different markets through packaging language, dosage instructions, climate-specific stability, and local OTC requirements. Miconazole vaginal products are established in multiple jurisdictions, but excipient names, labeling, product claims, and registration pathways vary.

What generic launch risks exist?

Generic and private-label launch risk is low from a patent perspective but meaningful operationally. The principal risks are:

• Active-ingredient supply interruptions
• Variability in miconazole particle size
• Suppository deformation during shipping
• Inadequate content uniformity
• Package seal failures
• Consumer complaints regarding leakage
• Incomplete stability data for hot climates
• Labeling errors involving treatment duration
• Confusion between vaginal and topical external use
• Retailer delisting due to slow turnover or quality complaints

A successful launch requires more than a compliant formula. The supplier must demonstrate reproducible batch performance, packaging robustness, and reliable service levels.

How strong is the patent estate for Basic Care Miconazole 3?

The patent estate is weak for the standard product and potentially stronger for differentiated delivery systems.

Asset	Patent strength	Commercial value
Ordinary miconazole nitrate suppository	Low	Low to moderate
Hydrogenated vegetable-oil base	Low	Necessary enabling technology
Heat-stable suppository architecture	Moderate if technically specific	Moderate
Mucoadhesive delivery	Moderate to strong if novel and validated	Potentially high
Novel applicator	Moderate	Moderate
Packaging design	Low to moderate	Moderate
Manufacturing process	Moderate if non-obvious and difficult to replicate	Moderate
Brand and retailer placement	Not patent-based	High practical value

The defensible commercial moat is more likely to come from manufacturing know-how, retailer relationships, quality performance, and brand architecture than from basic formulation patents.

What revenue exposure does Miconazole 3 create?

Public companies generally do not report revenue for an individual private-label SKU such as Basic Care Miconazole 3. Revenue exposure must therefore be assessed through category share, retailer distribution, unit velocity, and manufacturing contracts rather than reported product sales.

The relevant commercial variables are:

• Number of retail channels
• Retailer exclusivity
• Wholesale acquisition cost
• Gross margin after packaging and fulfillment
• Seasonal demand
• Repeat purchase rate
• Market share versus Monistat and store brands
• Product returns and complaint costs
• Capacity utilization at the manufacturing site

Because the product is inexpensive and mature, margin expansion depends on scale and operational efficiency. A premium formulation can improve unit economics, but the market remains price-sensitive.

Key Takeaways

• Basic Care Miconazole 3 is a three-day OTC vaginal antifungal product containing three 200 mg miconazole nitrate suppositories.
• The standard suppository uses a hydrogenated vegetable-oil base.
• The main formulation risks are leakage, thermal softening, drug dispersion, package compatibility, and consumer residue.
• Miconazole has no meaningful remaining composition-of-matter exclusivity.
• Orange Book listings and Paragraph IV challenges are generally not central to this OTC monograph product.
• Ordinary miconazole suppositories have weak patent protection.
• Stronger protection may be available for mucoadhesive systems, heat-stable bases, specialized applicators, or proprietary manufacturing processes.
• The largest commercial opportunities are private-label scale, premium leakage control, sustainable packaging, and broader vaginal-health portfolios.
• Manufacturing consistency and retailer access are more important competitive assets than basic patent ownership.

FAQs About Basic Care Miconazole 3

Is Basic Care Miconazole 3 the same as Monistat 3?

It is intended to provide the same active ingredient and three-day treatment format, but inactive ingredients, packaging, manufacturing site, labeling presentation, and quality specifications may differ.

Can a hydrogenated vegetable-oil suppository be used with condoms?

Oil-based vaginal products may weaken latex condoms and diaphragms. Consumers should follow the product label and use appropriate precautions during treatment.

Does miconazole 3 require a prescription?

No. Standard miconazole vaginal antifungal products are marketed over the counter when they comply with applicable FDA requirements.

Can a company patent a new miconazole suppository?

A company may pursue patents for a genuinely novel and non-obvious excipient system, release profile, applicator, packaging configuration, or manufacturing method. A routine miconazole suppository using a conventional lipid base is unlikely to support strong new patent protection.

What is the best commercial improvement for Miconazole 3?

The most practical improvement is a thermally robust suppository that reduces leakage while preserving dose uniformity, rapid release, low manufacturing cost, and compatibility with OTC monograph requirements.

References

1. Electronic Code of Federal Regulations. (2024). 21 C.F.R. § 333.455: Labeling of permitted combinations of active ingredients in vaginal antifungal drug products. https://www.ecfr.gov/

2. U.S. Food and Drug Administration. (2023). Over-the-counter monograph M005: Vaginal antifungal products. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. National Library of Medicine. (2024). DailyMed: Miconazole nitrate vaginal suppository labeling. https://dailymed.nlm.nih.gov/